Azilect (Rasagiline Mesylate) Patent Expiration, LOE Window & CMS Spending

Azilect (Rasagiline Mesylate) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2027-08-27, 10 AB generics, $1.4M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN021641 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-08-27
Last Listed Patent or Exclusivity Date2027-08-27
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$57K
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 30.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.